An observational study in Influenza A Virus Infection and Swine Flu, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Completed at 12 sites in United States. Open to male participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-08-19.
Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Observational
Background:
Objectives:
Eligibility:
Design:
Two types of influenza A widely circulate in humans and cause seasonal outbreaks and epidemics - H1N1 (swine flu) and H3N2 (a subtype abundant in seasonal influenza). During the 2009-2010 influenza season, the most commonly reported virus was influenza A (H1N1). However, during the 2010-2011 influenza season, the most commonly reported virus was influenza A (H3N2), but influenza A (H1N1) viruses and influenza B viruses circulated as well.
A certain age group may be hit harder by one type of influenza virus than another (for example, the 2009 H1N1 virus disproportionately affected people younger than 65 years of age rather than those older than 65, whereas H3N2 virus often affects those older than 65 years). However, influenza A has a substantial health effect on every age group.
Due to the limited therapeutic options for influenza and significant morbidity and mortality despite treatment, additional therapeutics are warranted. One potential therapeutic that is fairly rapidly available is the use of anti-influenza A immune plasma as immunotherapy.
The objective of this protocol is collection of anti-influenza A immune plasma from male volunteers that meet criteria for use in human plasma therapy studies. The use of plasma from male donors will minimize the risk of transfusion related acute lung injury (TRALI), which has been associated with antibodies (likely generated during pregnancy) found in female plasma. For this reason, only male donors will be enrolled.
This protocol does not administer any investigational product, but rather collects plasma from subjects with a high anti-influenza A antibody titer (convalescent survivors of influenza infection or recipients of a licensed influenza vaccine).
Following screening of potential subjects to identify those who are not eligible to participate in plasma donations and to determine the likelihood of having antibodies to influenza A (H1N1 or H3N2) from a recent infection or immunization, enrolled subjects will receive a baseline physical and laboratory examination. Eligible subjects with high influenza A hemagglutination inhibition (HAI) titers will then be scheduled for at least 3 (and up to 20) plasma collection sessions. Following testing of the collected plasma for potential pathogens, it may be used as therapeutic plasma, and/or it may be used for the manufacturing of high titer anti-influenza A intravenous immune globulin (IVIG). Both options would support clinical trials aimed at developing additional therapeutics for influenza infection.
2,214 studies on the registry are indexed under Influenza, Human; 163 are open to participants now.
This study's enrollment of 102 is below the median of 300 across 305 observational studies indexed under Influenza, Human.
Browse Influenza, Human studies →National Institute of Allergy and Infectious Diseases (NIAID) is the lead sponsor of 2,401 studies on the registry; 179 are open to participants now.
Of its 396 completed or terminated interventional studies of FDA-regulated products, 294 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Male subjects with a history consistent with influenza infection and/or vaccination against influenza.
Provide written informed consent before initiation of any study procedures.
History suggestive of having anti-influenza A antibodies (either of the following):
Adequate clinical parameters (all of the following):
EXCLUSION CRITERIA:
<!-- -->
Any sign of active influenza, (as judged by the investigator) including but not limited to:
Has a medical history of
History of cancer that meets any one of the following criteria:
Medication history that includes any of the following:
Has ever had any of the following:
Within the 8 weeks prior to enrollment:
a. Was vaccinated with the small pox vaccine, or was in close contact with someone who was vaccinated (i.e., close family member)
Within the 4 months prior to enrollment has had:
a. A blood donation of a double unit of red cells
Within the 12 months prior to enrollment has:
Within the last 12 months has had sexual contact with (any of the following):
Participation in medical research that includes:
PLASMA DONATION CRITERIA (all of the following):
Adequate laboratory parameters from screening (must meet all of the criteria below)
Quantitative immune globulin levels (all of the following)
Negative serologic and molecular tests for blood borne pathogens, to include:
High titer influenza A plasma collection for use as therapeutic plasma in influenza treatment studies.
Collection of Anti-Influenza A Immune Plasma
Subjects will be scheduled for at least 3, and up to 20, plasma collection procedures.
Time frame: Individual duration is a maximum of 240 days per subject.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Institute of Allergy and Infectious Diseases (NIAID)